arrow
D

David Spetzler

caris life sciences
H指数:26
被引数:9,503

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Corrigendum to “Whole-exome sequencing provides assessment of homologous recombination deficiency for identification of PARPi-responsive ovarian tumors” [Gynecol. Oncol. 197 (2025) 139–145]

勘误:“全外显子组测序为评估同源重组缺陷以识别对PARPi敏感的卵巢肿瘤” [Gynecol. Oncol. 197 (2025) 139–145]

2026-10-210
PRE
The conformation-selective PI3Kδ inhibitor roginolisib in patients with advanced or metastatic cancer, including metastatic uveal melanoma: first-in-human clinical trial

在晚期或转移性癌症患者中具有构象选择性的PI3Kδ抑制剂roginolisib的临床试验:首次人体试验,包括转移性葡萄膜黑色素瘤

2026-10-090
OAAI
Broader gene representation by whole-exome sequencing improves accuracy of tumor mutational burden assessment for selection of pembrolizumab immunotherapy

全外显子组测序获得更广泛的基因表达可提高肿瘤突变负荷评估的准确性,以选择帕博利珠单抗免疫疗法

2026-05-110
OAAI
Genomic and Immune Correlates of EZH2 Expression and Activity in Olfactory Neuroblastoma

EZH2表达和活性的基因组与免疫相关性在嗅神经母细胞瘤中的研究

2025-11-010
OAAI
Author Correction: Synergistic H&E and IHC image analysis by AI predicts cancer biomarkers and survival outcomes in colorectal and breast cancer

作者更正:AI协同H&E和IHC图像分析预测结直肠癌和乳腺癌的癌症生物标志物和生存结局

2025-10-240
OA
Synergistic H&E and IHC image analysis by AI predicts cancer biomarkers and survival outcomes in colorectal and breast cancer

人工智能协同分析H&E与IHC图像,预测结直肠癌和乳腺癌的癌生物标志物及生存结局

2025-08-010
OAAI
REFINE: a database of linked clinical data and genomic biomarkers in renal cell carcinoma patients receiving immunotherapy-based treatment regimens

REFINE:接受基于免疫疗法治疗方案的肾细胞癌患者中,包含关联临床数据和基因组生物标志物的数据库

2025-06-010
OAAI
Mutation burden and anti-PD-1 outcomes are not universally associated with immune cell infiltration or lymphoid activation

突变负担和抗PD-1疗效与免疫细胞浸润或淋巴样细胞激活之间并非普遍相关。

2024-12-010
PRE
Temporal stability and chemotherapy responsiveness of classical and basal transcriptional subtypes of pancreatic cancer
2024-09-150
PRE
Tissue-specific thresholds of mutation burden associated with anti-PD-1/L1 therapy benefit and prognosis in microsatellite-stable cancers
2024-03-252
PRE
Tissue- specific thresholds and microenvironment correlates of tumor mutation burden associated with immunotherapy benefit and prognosis in microsatellite stable cancers
2024-03-220
PRE